EUVIMEDEUVIMED entdecken
Crossref

Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis

Ryma Terbah, Anoop N Koshy, Avik Majumdar, Karl Vaz, Adam Testro, Marie Sinclair

Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1375-1383

DOI: 10.1016/j.cgh.2024.08.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Ryma Terbah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Melbourne, Victoria, Australia; Victorian Liver Transplant Unit, Austin Health, Heidelberg, Australia; Australi…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Lypressin, Vasoconstrictor Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Austin Medical Research Foundation, Mallinckrodt Pharmaceuticals, Mallinckrodt Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Cardiac dysfunction is a key factor in the pathogenesis of hepatorenal syndrome, for which terlipressin is the recommended first-line treatment. This study investigates whether long-term terlipressin can ameliorate the subclinical cardiac dysfunction observed in decompensated cirrhosis. METHODS: Twenty-two patients with decompensated cirrhosis and ascites enrolled in a prospective study of home continuous terlipressin infusion were included. Cardiac function was assessed using dobutamine stress echocardiogram before and after 12 weeks of terlipressin. The primary outcome was the impact of terlipressin on cardiac reserve, the change in cardiac output (CO) in response to stress. RESULTS: The median age was 61 years (interquartile range, 56-64 years), the median Model for End-Stage Liver Disease score was 15 (interquartile range, 12.3-17.0), and 72.7% were male. The increase in CO in response to low-dose dobutamine was significantly higher following terlipressin (↑4.0 L/min [↑57.8%]) as compared with baseline (↑1.8 L/min [21.3%]) (P = .0001). The proportion of patients with impaired cardiac reserve (defined by ΔCO

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisLypressinVasoconstrictor AgentsHumansTerlipressinMaleMiddle AgedFemaleProspective StudiesTreatment OutcomeAgedInfusions, Intravenous

Stichwörter der Autor:innen

Cardiac FunctionCardiomyopathyCirrhosisPortal HypertensionTerlipressin

Substanzen

TerlipressinLypressinVasoconstrictor Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Melbourne, Victoria, Australia; Victorian Liver Transplant Unit, Austin Health, Heidelberg, Australia; Australian Centre for Transplantation Excellence and Research, Melbourne, Aust…

Förderung

  • Austin Medical Research Foundation
  • Mallinckrodt Pharmaceuticals
  • Mallinckrodt Inc

Zitieren

APA

Terbah, R., Koshy, A. N., Majumdar, A., Vaz, K., Testro, A., & Sinclair, M. (2026). Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 24(5), 1375-1383. https://doi.org/10.1016/j.cgh.2024.08.010

Vancouver

Terbah R, Koshy AN, Majumdar A, Vaz K, Testro A, Sinclair M. Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2026;24(5):1375-1383. doi:10.1016/j.cgh.2024.08.010

BibTeX
@article{Terbah2026,
  author = {Terbah, Ryma and Koshy, Anoop N and Majumdar, Avik and Vaz, Karl and Testro, Adam and Sinclair, Marie},
  title = {Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {1375--1383},
  doi = {10.1016/j.cgh.2024.08.010}
}
Kostenlos starten →